Effects of LY303870 on secondary pharmacological evaluation
| Test | Species (Route) |
|---|---|
| Startle responsiveness (sensorimotor reactivity)2-a | Mouse (i.p., p.o.) |
| Spontaneous activity (behavioral depression)2-a | Mouse (i.p., p.o.) |
| Grip strength (neuromuscular function)2-a | Mouse (i.p., p.o.) |
| Hexobarbital-induced sleep times (central nervous system depression)2-a | Mouse (p.o.) |
| Electroshock- or pentelenetetrazol-induced convulsions (convulsive liability)2-a | Mouse (p.o.) |
| Rotarod performance (coordination)2-a | Rat (i.p., p.o.) |
| Body temperature2-a | Mouse (p.o.) |
| Cardiovascular function2-b | Rat (p.o.) |
| Clinical signs (behavioral observations)2-a | Mouse (i.p., p.o.) |
| Charcoal meal transit (gastrointestinal function)2-b | Mouse (p.o.) |
There was no activity in any of the tests listed at doses of LY303870 of ≤30 mg/kg i.p. for the free base or 50 mg/kg p.o. For the dihydrochloride trihydrate salt, when tested in mice or rats (n = 10, except n = 4 for cardiovascular function), with the exception of 50 mg/kg p.o., which produced a slight but significant increase in heart rate only. However, this increase was not considered to be physiologically relevant. These results suggest no evidence of neurological deficits, behavioral depression or disruption of autonomic function at the doses tested.